Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
abetted, absence, accomplished, Ajay, Ajinomoto, Albayrak, alia, analytical, analyzing, appoint, appointed, appointment, ASP, assumption, avoid, begun, bioavailability, biopharmaceutical, biosimilar, Biosimilarity, BLA, BPCIA, breakdown, Canadian, cancer, Carneiro, carrier, Category, cell, CEO, CFO, CGT, Chancery, Christiansen, clarification, composition, contamination, Csaba, CVR, cybersecurity, Dan, deadline, deploy, deployment, destruction, dictated, diminished, disaggregated, dissemination, easily, efbemalenograstim, eflapegrastim, electrical, engineering, enterprise, equitable, escalate, excuse, febrile, formula, fractional, frequency, FULPHILA, FYLNETRA, geopolitical, Georgia, GPO, granulocyte, Guggenheim, guideline, half, Hanmi, harmonize, Heather, hinder, implicated, inadvertent, incorrect, indefinite, infection, instability, Interchangeability, interchangeable, ion, irreversible, Johnson, juncture, kinase, Korea, leave, lessee, licensee, literature, lost, lung, Luo, malware, Mason, maximum, meaningful, midst, misappropriation, misled, misuse, moiety, molecular, molecule, myelosuppressive, NCE, Neulasta, neutropenia, nominal, noncurrent, nonmyeloid, notably, NYVEPRIA, oncology, Patel, Paul, PCI, pegfilgrastim, Peisert, pendency, penetration, Petition, pharmacologic, PHSA, physiological, potency, potent, poziotinib, prioritize, provisional, prudent, pure, purpose, randomized, Raul, reassessment, recession, recipient, reconciling, recourse, redundant, Repayment, replead, resubmission, RLD, rolvedon, ROLVEDONTM, ROVELDON, RYZNEUTA, Schwichtenberg, Shapiro, Shumacher, slightly, slowdown, smooth, social, Southern, Spectrum, stable, standing, Steven, STIMUFEND, stockholder, subtitle, suggest, Suitability, suitable, switched, telecommunication, Tex, thereunder, tier, Turgeon, tyrosine, UDENYCA, underperforming, uniformly, unify, unjustly, Unlisted, unspecified, vi, Vice, war, worth, ZIEXTENZO
Removed:
accompanied, adapted, adjusted, agent, Alabama, Arizona, ascertaining, building, buying, Cal, Carolina, carryback, CII, circumstance, collateral, collectible, Colorado, core, custom, Delinquent, derecognized, disallowance, discourage, dispensing, distribute, efficiency, enact, enrichment, ESPP, factual, filling, footprint, freestanding, FSB, global, grouping, growing, Hampshire, handle, HCI, Huang, hydrochloride, iCeutica, impactful, influenced, instrument, Island, Jersey, legitimate, low, Maine, mandate, medicinal, minimal, narcotic, opportunistically, outbreak, oxycodone, package, pandemic, payroll, PBM, placement, platform, positioned, preceding, prescriber, procurement, promise, QSR, quickly, refilling, refuse, remote, renew, renewed, reset, revoke, Rhode, run, scaled, seamlessly, snorting, Society, substitute, sustained, track, transformation, TSR, unjust, unsuccessful, UPM, USP, variation, Vermont, Virginia, virtual, Washington, waste, Wayne, Wilmington, Wisconsin
Financial report summary
?Competition
Marinus PharmaceuticalsRisks
- We are subject to risks from changes in laws and regulations applicable to, and increased scrutiny and investigations of, the pharmaceutical industry, including the opioid market, which can adversely affect our business, financial condition and results of operations.
Management Discussion
- ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
- We are a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products. Our comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting, and trade and distribution. Our primary marketed products are:
- On July 31, 2023 (the “Effective Date”), pursuant to an Agreement and Plan of Merger (the “Merger Agreement”), dated as of April 24, 2023, we completed the acquisition of Spectrum Pharmaceutical, Inc. (“Spectrum”), a commercial stage biopharmaceutical company focused on novel and targeted oncology products (the “Spectrum Merger”), through a merger of a wholly-owned subsidiary of the Company with and into Spectrum, with Spectrum surviving the merger as a wholly-owned subsidiary of the Company. We accounted for the Spectrum Merger using the acquisition method of accounting under Accounting Standards Codification (“ASC”) 805 (“ASC 805”) and are considered the accounting acquirer. The results of operations of Spectrum are included in our consolidated financial statements as of the Effective Date.